Abstract:Background: The ability to generate functional hepatocytes without relying on donor liver organs holds significant therapeutic promise in the fields of regenerative medicine and potential liver disease treatments. Clustered regularly interspaced short palindromic repeats (CRISPR) activator (CRISPRa) is a powerful tool that can conveniently and efficiently activate the expression of multiple endogenous genes simultaneously, providing a new strategy for cell fate determination. The main purpose of this study is to explore the feasibility of applying CRISPRa for hepatocyte reprogramming and its application in the treatment of mouse liver fibrosis. Method: The differentiation of mouse embryonic fibroblasts (MEFs) into functional induced hepatocyte-like cells (iHeps) was achieved by utilizing the CRISPRa synergistic activation mediator (SAM) system, which drove the combined expression of three endogenous transcription factors—Gata4, Foxa3, and Hnf1a—or alternatively, the expression of two transcription factors, Gata4 and Foxa3. In vivo, we injected adeno-associated virus serotype 6 (AAV6) carrying the CRISPRa SAM system into liver fibrotic Col1a1-CreER; Cas9fl/fl mice, effectively activating the expression of endogenous Gata4 and Foxa3 in fibroblasts. The endogenous transcriptional activation of genes was confirmed using real-time quantitative polymerase chain reaction (RT-qPCR) and RNA-seq, and the morphology and characteristics of the induced hepatocytes were observed through microscopy. The level of hepatocyte reprogramming in vivo is detected by immunofluorescence staining, while the improvement of liver fibrosis is evaluated through Sirius red staining, alpha-smooth muscle actin (α-SMA) immunofluorescence staining, and blood alanine aminotransferase (ALT) examination. Results: Activation of only two factors, Gata4 and Foxa3, via CRISPRa was sufficient to successfully induce the transformation of MEFs into iHeps. These iHeps could be expanded in vitro and displayed functional characteristics similar to those of mature hepatocytes, such as drug metabolism and glycogen storage. Additionally, AAV6-based delivery of the CRISPRa SAM system effectively induced the hepatic reprogramming from fibroblasts in mice with live fibrosis. After 8 weeks of induction, the reprogrammed hepatocytes comprised 0.87% of the total hepatocyte population in the mice, significantly reducing liver fibrosis. Conclusion: CRISPRa-induced hepatocyte reprogramming may be a promising strategy for generating functional hepatocytes and treating liver fibrosis caused by hepatic diseases.

Conversion of Fibroblasts to Hepatocyte-Like Cells in Vivo.

Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis

Converting Skin Fibroblasts into Hepatic-Like Cells by Transient Programming

Direct Reprogramming of Human Fibroblasts to Functional and Expandable Hepatocytes.

Reprogramming Fibroblasts into Bipotential Hepatic Stem Cells by Defined Factors

Conversion of hepatoma cells to hepatocyte-like cells by defined hepatocyte nuclear factors

Direct reprogramming of fibroblasts into functional hepatocytes via CRISPRa activation of endogenous Gata4 and Foxa3

Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors

Efficient Generation of Functional Hepatocyte-Like Cells from Mouse Liver Progenitor Cells Via Indirect Co-Culture with Immortalized Human Hepatic Stellate Cells.

Direct Chemical Induction of Hepatocyte‐like Cells with Capacity for Liver Repopulation

The therapeutic potential of induced hepatocyte-like cells generated by direct reprogramming on hepatic fibrosis

Human Hepatocytes with Drug Metabolic Function Induced from Fibroblasts by Lineage Reprogramming

Therapeutic Cell Repopulation of the Liver: From Fetal Rat Cells to Synthetic Human Tissues

Hepatocyte Differentiation of Human Fibroblasts from Cirrhotic Liver in Vitro and in Vivo

Reprogramming Fibroblasts Toward Cardiomyocytes, Neural Stem Cells and Hepatocytes by Cell Activation and Signaling-Directed Lineage Conversion

Small Molecules Facilitate Single Factor-Mediated Hepatic Reprogramming

Reprogramming the spleen into a functioning 'liver' in vivo

In Vitro Culture of Isolated Primary Hepatocytes and Stem Cell-Derived Hepatocyte-Like Cells for Liver Regeneration

Fibroblasts Derive from Hepatocytes in Liver Fibrosis via Epithelial to Mesenchymal Transition

Direct Lineage Conversion of Terminally Differentiated Hepatocytes to Functional Neurons.

Conversion of Fibroblast into Functional Leydig-like Cell Using Defined Small Molecules